IBA – Transparency Notification - Seite 2

• Additional Information

Passive crossing following the introduction of the loyalty vote and new thresholds in the Issuer's articles of association.
Reminder of the legal status of UCLouvain: legal person under private law pursuing an aim of public utility and enjoying civil personality under a law of 12 August 1911 modified by a law of 28 May 1970.

For further information, please contact:

IBA

Elodie Jaumain
Paralegal
[phone]

[e-mail]

About IBA

IBA (Ion Beam Applications) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com

 

 

Attachment

• 20200528transparencyUCL_SOPARTEC_EN(au-dessus2%)